The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

Baird lowered the firm’s price target on Editas Medicine (EDIT) to $10 from $18 and keeps an Outperform rating on the shares. The firm ...

Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.

Roivant's high valuation is justified, with a strong cash position, promising drug pipeline, and strategic partnerships ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

Avacta Therapeutics has entered a strategic collaboration with Tempus AI to advance the development of drugs in oncology.

Editas Medicine (EDIT) and Genevant Sciences announced that they have entered into a collaboration and nonexclusive license agreement to ...

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sci ...

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid ...